TITLE

Canagliflozin

AUTHOR(S)
Cada, Dennis J.; Ingram, Kyle T.; Levien, Terri L.; Baker, Danial E.
PUB. DATE
November 2013
SOURCE
Hospital Pharmacy;Nov2013, Vol. 48 Issue 10, p855
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on clinical pharmacology, pharmacokinetics and efficacy of drug Canagliflozin. It mentions that Canagliflozin lowers blood glucose in a dose dependent manner by lowering the renal threshold for glucose and increasing the excretion of glucose by inhibition of renal sodium glucose transport proteins. It states that bioavailability of the drug is 65 percent and informs that high fat meal has no effect on the pharmacokinetics of the drug.
ACCESSION #
91860268

 

Related Articles

  • Vildagliptin: Efficacy and tolerability in RI.  // Diabetes Digest;2012, Vol. 11 Issue 1, p25 

    The article presents a study which examines the efficacy of triple oral polypill for the treatment of type 2 diabetes (T2D).

  • Luseogliflozin: First Global Approval. Markham, Anthony; Elkinson, Shelley // Drugs;Jun2014, Vol. 74 Issue 8, p945 

    Luseogliflozin [Lusefi (Japan)] is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). The drug has received its first global approval for this indication in...

  • Takeda launches Vipidia (alogliptin) in the UK.  // Diabetes Digest;2014, Vol. 13 Issue 1, p38 

    The article offers brief information on the launch of Vipidia as an inhibitor class of drugs designed as an add-on therapy for the treatment of type 2 diabetes in adults, from Takeda.

  • The Effect of Basal Analog Insulin on the Glycemic Variability in Type 2 Diabetics. Cander, Soner; Gül, Özen Öz; Dizdar, Oğuzhan Sıtkı; Aydın, Taner; Ersoy, Canan // Turkish Journal of Endocrinology & Metabolism;6/1/2014, Vol. 18 Issue 2, p33 

    Purpose: The aim of this study was to investigate the effect of insulin detemir and glargine on glycemic variability as determined by capillary blood glucose measurements in Type 2 diabetics treated with oral antidiabetic drugs. Material and Method: A total of 64 insulin-naive type 2 diabetics...

  • Alogliptin. Cada, Dennis J.; Levien, Terri L.; Baker, Danial E. // Hospital Pharmacy;Jul2013, Vol. 48 Issue 7, p580 

    The article offers information on the alogliptin which is used for the treatment of patients with type two diabetes mellitus and for improving glycenic control in adults. It discusses the combination of alogliptin with other antidiabetic agents including pioglitazone, sulfonylureas and insulin....

  • Dapagliflozin: A Once-Daily Oral Therapy Sodium-Glucose Cotransporter-2 Inhibitor for the Treatment of Adult Patients with Type 2 Diabetes. Jadoon, Khalid; Idris, Iskandar // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p185 

    The induction of glycosuria using phlorizin, a nonselective inhibitor of renal and intestinal transport was well recognised to lower glucose levels and induce calorie loss in animal models of diabetes. Phlorizin and other similar molecules however were not suitable for clinical use due to...

  • Formulary Drug Reviews: Exenatide Extended-Release Injection. Cada, Dennis J.; Levien, Terri L.; Baker, Danial E. // Hospital Pharmacy;Aug2012, Vol. 47 Issue 8, p633 

    The article reviews exenatide extended-release (ER) injection (Bydureon), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The clinical pharmacology of the drug and its pharmacokinetics are described together with...

  • Dapagliflozin maintains HR-QOL in diabetes.  // PharmacoEconomics & Outcomes News;10/27/2012, Issue 665, p10 

    The article reports on an international, double-blind clinical trial on the impact of dapagliflozin in health-related quality of life (HR-QOL) of patients with type 2 diabetes.

  • New oral therapies for type 2 diabetes. Purnell, Jonathan Q.; Hirsch, Irl B. // American Family Physician;11/1/1997, Vol. 56 Issue 7, p1835 

    Provides information on several oral agents for the treatment of type two diabetes available in the United States. Side effects of metformin, acarbose, troglitazone; Its mechanism of action of the drugs; Adverse effects of the drugs.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics